VKTX down again after earnings. Looks like it wants to fill the support at 26 perhaps if continues lower. Brief coverage provided but as with my last update, not averaging into this weakness.
Need to see more from price action to invest more into the stock, rather than chasing losers. I am basically forgetting I own the company for now and concentrating on other names in my portfolio to counter act weakness in vktx. If you have a diversified portfolio as you always should you will be able to get through weakness in individual names by concentrating on better performing names. Best not to waste Cash flow in a bull market chasing lsoers where that can be put towards more viable positions that are still discounted like some of the AI names.
Cash looks healthy, still got a best in class product. Catalysts ahead look vague hence the price action we are seeing in after hours.
It will see its day but its not today. Best to average when it shows sign of reversal. Breaking above the 21d ema would be the best signal.
Managing lsoers is also a skill just as managing winners is.
#transparency
Currently sitting at $32/share and ~$3.6B MC.
- Cash balance ~$903M
- Pipeline w/ 2 candidates about to enter Ph3 development & 1 in Ph2
• VK2735 inj obesity/diabetes candidate entering two Ph3 trials in 2Q25
• VK2809 in NASH Ph3 initiation TBD
• Potential best in class Oral Dual GLP1/GIP agonist candidate currently in 13 week Ph2 trial
- Obesity market projected to reach >$200B by 2030
CATALYSTS AHEAD
- Any news on potential partnership or deal with a global supplier - announcement in “near future”
- Inj VK2735 two Ph3 trials initiation planned 2Q25.
- Oral Vk2735 Ph2 meeting and data update 2H2025
On manufacturing
